Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2014

View Archived Issues

FDA grants triheptanoin orphan drug status for GLUT-1 deficiency syndrome

Researchers use germline DNA gene editing to prevent muscular dystrophy in mice

Development of a receptor tyrosine kinase decoy as a potential anticancer therapy

Clenbuterol earns FDA orphan drug designation as adjunctive therapy for Pompe's disease

Papillary thyroid carcinoma predisposition linked to a mutation in the SRRM2 gene

IL28B gene polymorphisms examined in chronic hepatitis B

Triphase expands collaboration with Celgene

Ventana Medical Systems to develop companion diagnostics for ImmunoGen

New gene linked to Charcot-Marie-Tooth disease

Novartis reflects on accomplishments of third quarter 2014

Bristol-Myers Squibb reports new HIV integrase inhibitors

PATH reports on phase I/IIb study of ACE-527 ETEC vaccine

Osteros Biomedica begins phase I trial of MBC-11

Shire reports pipeline progress of third quarter 2014

Saniona acquires obesity candidate from NeuroSearch

Cara Therapeutics reports data from CR-845 trial

Dr. Falk Pharma enrolls first patients in phase III trial of LT-02

FDA grants accelerated approval to Trumenba for prevention of meningococcal meningitis B

FDA approves Xigduo XR for type 2 diabetes

FDA grants fast track designation to Novavax's H7N9 VLP vaccine candidate

Alkem and Georgetown University patent Flavivirus protease inhibitors

New LpxC inhibitors reported by Achaogen

GW Pharmaceuticals initiates phase II/III study of Epidiolex for Dravet syndrome

Roche patents new BTK inhibitors

Quanticel Pharmaceuticals presents new histone demethylase inhibitors

Imago Biosciences reports new KDM1A inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...